Wolfe Research Lifts PT for Johnson & Johnson (JNJ), Keeps Outperform Rating

Johnson & Johnson (NYSE:JNJ) is one of the 10 Unrivaled Stocks of the Next 3 Years. On September 3, Wolfe Research increased the price target for Johnson & Johnson (NYSE:JNJ) from $175 to $195 and kept an Outperform rating.

Wolfe Research cited growing confidence in Johnson & Johnson’s (NYSE:JNJ) upcoming talc litigation outcome. This confidence led the firm to use lower weighted average cost of capital (WACC) assumptions in its discounted cash flow analysis.

The research firm pointed out some challenges for the pharmaceutical industry in 2025. These include sector-specific tariffs and Most-Favored-Nation prescription drug pricing, which aims to reduce prescription drug prices for Americans.

Despite these challenges, Wolfe Research has a positive outlook on Johnson & Johnson’s (NYSE:JNJ) growth prospects, especially from its Innovative Medicine division.

Johnson & Johnson (NYSE:JNJ) is an American multinational healthcare company that specializes in pharmaceuticals and medical technologies.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 10 Stocks Under $10 That Could Triple and 10 Best Affordable Stocks Under $50 to Buy.

Disclosure: None. This article is originally published at Insider Monkey.